Market Closed -
Nyse
04:00:00 2024-05-16 pm EDT
|
5-day change
|
1st Jan Change
|
2.04
USD
|
-1.45%
|
|
-13.19%
|
-48.74%
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
250
|
117.4
|
140.3
|
65.04
|
24.2
|
32.92
|
-
|
-
|
Enterprise Value (EV)
1 |
250
|
117.4
|
140.3
|
65.04
|
24.2
|
32.92
|
32.92
|
32.92
|
P/E ratio
|
7.25
x
|
-5.12
x
|
-4.36
x
|
-1.85
x
|
-0.83
x
|
-0.88
x
|
-1.73
x
|
1.09
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
4.15
x
|
995
x
|
-744
x
|
44.3
x
|
4.99
x
|
7.98
x
|
6.27
x
|
0.44
x
|
EV / Revenue
|
4.15
x
|
995
x
|
-744
x
|
44.3
x
|
4.99
x
|
7.98
x
|
6.27
x
|
0.44
x
|
EV / EBITDA
|
6.98
x
|
-4.99
x
|
-4.21
x
|
-
|
-0.75
x
|
-0.77
x
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
8,622
|
9,170
|
9,202
|
9,271
|
11,523
|
16,137
|
-
|
-
|
Reference price
2 |
29.00
|
12.80
|
15.25
|
7.015
|
2.100
|
2.040
|
2.040
|
2.040
|
Announcement Date
|
9/12/19
|
9/25/20
|
9/28/21
|
9/22/22
|
9/28/23
|
-
|
-
|
-
|
Fiscal Period: Juni |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
60.3
|
0.118
|
-0.1886
|
1.468
|
4.854
|
4.127
|
5.25
|
74.48
|
EBITDA
1 |
35.8
|
-23.54
|
-33.33
|
-
|
-32.17
|
-43
|
-
|
-
|
EBIT
1 |
35.74
|
-23.61
|
-33.38
|
-36.59
|
-32.46
|
-23.53
|
-34.42
|
37.49
|
Operating Margin
|
59.28%
|
-20,007.44%
|
17,701.01%
|
-2,491.62%
|
-668.75%
|
-570.13%
|
-655.64%
|
50.33%
|
Earnings before Tax (EBT)
1 |
35.77
|
-22.43
|
-33.6
|
-36.2
|
-32.22
|
-34.8
|
-33.94
|
37.95
|
Net income
1 |
35.77
|
-22.43
|
-33.6
|
-36.2
|
-27.54
|
-34.61
|
-30.67
|
30.36
|
Net margin
|
59.32%
|
-19,006.71%
|
17,813.63%
|
-2,465.05%
|
-567.44%
|
-838.76%
|
-584.17%
|
40.76%
|
EPS
2 |
4.000
|
-2.500
|
-3.500
|
-3.790
|
-2.530
|
-2.313
|
-1.180
|
1.880
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/12/19
|
9/25/20
|
9/28/21
|
9/22/22
|
9/28/23
|
-
|
-
|
-
|
Fiscal Period: June |
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 Q3
|
---|
Net sales
1 |
0.1595
|
0.3221
|
0.2161
|
0.7707
|
0.8696
|
1.026
|
1.196
|
1.762
|
2.106
|
2.034
|
0.0807
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-7.203
|
-8.424
|
-7.776
|
-
|
-8.693
|
-6.544
|
-7.223
|
-10.74
|
-6.022
|
1.258
|
-10.7
|
-10.3
|
-
|
-
|
-
|
EBIT
1 |
-7.216
|
-8.451
|
-7.82
|
-13.1
|
-8.753
|
-6.614
|
-7.301
|
-10.82
|
-6.109
|
1.173
|
-9.218
|
-9.374
|
-9.732
|
-10.4
|
-11.13
|
Operating Margin
|
-4,524.55%
|
-2,623.45%
|
-3,618.88%
|
-1,699.81%
|
-1,006.46%
|
-644.39%
|
-610.64%
|
-613.99%
|
-290.07%
|
57.67%
|
-10,200.2%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-7.113
|
-8.686
|
-7.632
|
-12.77
|
-8.255
|
-6.099
|
-7.148
|
-10.71
|
-5.888
|
-7.844
|
-8.436
|
-9.687
|
-9.605
|
-10.28
|
-11
|
Net income
1 |
-7.113
|
-8.686
|
-7.632
|
-12.77
|
-8.255
|
-1.424
|
-7.148
|
-10.71
|
-5.888
|
-7.844
|
-8.436
|
-9.077
|
-9.605
|
-10.28
|
-11
|
Net margin
|
-4,459.88%
|
-2,696.49%
|
-3,531.51%
|
-1,656.54%
|
-949.28%
|
-138.74%
|
-597.81%
|
-608.11%
|
-279.6%
|
-385.62%
|
-10,405.36%
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.7500
|
-1.000
|
-0.7500
|
-1.340
|
-0.8600
|
-0.1300
|
-0.6300
|
-0.9100
|
-0.4800
|
-0.5600
|
-0.5300
|
-0.5100
|
-0.2600
|
-0.2400
|
-0.1900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/15/21
|
2/14/22
|
5/16/22
|
9/22/22
|
11/14/22
|
2/14/23
|
5/15/23
|
9/28/23
|
11/14/23
|
2/14/24
|
5/15/24
|
-
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.06
|
0.01
|
0.26
|
0.43
|
0.04
|
0.19
|
-
|
Capex / Sales
|
-
|
53.29%
|
-3.03%
|
17.8%
|
8.94%
|
0.92%
|
3.64%
|
-
|
Announcement Date
|
9/12/19
|
9/25/20
|
9/28/21
|
9/22/22
|
9/28/23
|
-
|
-
|
-
|
Last Close Price
2.04
USD Average target price
11.5
USD Spread / Average Target +463.73% Consensus |
1st Jan change
|
Capi.
|
---|
| -48.74% | 33.4M | | +8.29% | 113B | | +10.21% | 106B | | +0.41% | 22.27B | | -11.90% | 22.22B | | -5.99% | 19.43B | | -37.36% | 17.87B | | -5.17% | 17.24B | | +7.70% | 14.29B | | +37.65% | 12.52B |
Bio Therapeutic Drugs
|